ArticleProceedings of the National Academy of Sciences of the United States of America2001
Antisense DNAs as multisite genomic modulators identified by DNA microarray.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 81 citations in OpenAlex.
- Managing the sequence-specificity of antisense oligonucleotides in drug discovery.Nucleic acids research · 2017Review
- Regulatory subunits of PKA define an axis of cellular proliferation/differentiation in ovarian cancer cells.BMC medical genomics · 2008Article
- Poly(propylacrylic acid) enhances cationic lipid-mediated delivery of antisense oligonucleotides.Biomacromolecules · 2006Article
- The lentiginoses: cutaneous markers of systemic disease and a window to new aspects of tumourigenesis.Journal of medical genetics · 2005Review
- Article
- Epigenetic manipulation of gene expression: a toolkit for cell biologists.The Journal of cell biology · 2005Review
- Direct comparison of the specificity of gene silencing using antisense oligonucleotides and RNAi.The Biochemical journal · 2005Article
- Employment of microarray analysis to characterize biologic differences associated with tropism-modified adenoviral vectors: utilization of non-native cellular entry pathways.Cancer gene therapy · 2005Article
- Protein kinase A isozyme switching: eliciting differential cAMP signaling and tumor reversion.Oncogene · 2004Article
- Toward a functional annotation of the human genome using artificial transcription factors.Genome research · 2003Article
- Zinc-finger protein-targeted gene regulation: genomewide single-gene specificity.Proceedings of the National Academy of Sciences of the United States of America · 2003Article
- Specificity of short interfering RNA determined through gene expression signatures.Proceedings of the National Academy of Sciences of the United States of America · 2003Article
- Analysis of microarray data using Z score transformation.The Journal of molecular diagnostics : JMD · 2003Article
- A genomic-scale view of the cAMP response element-enhancer decoy: a tumor target-based genetic tool.Proceedings of the National Academy of Sciences of the United States of America · 2002Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Antisense oligodeoxynucleotides can selectively block disease-causing genes, and cancer genes have been chosen as potential targets for antisense drugs to treat cancer. However, nonspecific side effects have clouded the true antisense mechanism of action and hampered clinical development of antisense therapeutics. Using DNA microarrays, we have conducted a systematic characterization of gene expression in cells exposed to antisense, either exogenously or endogenously. Here, we show that in a sequence-specific manner, antisense targeted to protein kinase A RIalpha alters expression of the clusters of coordinately expressed genes at a specific stage of cell growth, differentiation, and activation. The genes that define the proliferation-transformation signature are down-regulated, whereas those that define the differentiation-reverse transformation signature are up-regulated in antisense-treated cancer cells and tumors, but not in host livers. In this differentiation signature, the genes showing the highest induction include genes for the G proteins Rap1 and Cdc42. The expression signature induced by the exogenously supplied antisense oligodeoxynucleotide overlaps strikingly with that induced by endogenous antisense gene overexpression. Defining antisense DNAs on the basis of their effects on global gene expression can lead to identification of clinically relevant antisense therapeutics and can identify which molecular and cellular events might be important in complex biological processes, such as cell growth and differentiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.